Is BPC-157 from Lumera Labs HPLC verified?

Yes. Every BPC-157 lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is BPC-157 sold for human use?

No. BPC-157 is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is BPC-157 shipped?

BPC-157 is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for BPC-157?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

For laboratory research use only. Not for human consumption. Free cold-chain shipping over $60 CAD · Ships from Kelowna, BC

Free cold-chain shipping over $200 CAD · Ships from Kelowna, BC

Track order My account Wishlist Contact

LUMERA LABS

4.8 · 45 researcher reviews

Healing · Body Protection Compound

BPC-157

SKU LUM-BPC157-5 · C₆₂H₉₈N₁₆O₂₂ · 1419.55 g/mol · CAS 137525-51-0

A 15-amino-acid partial sequence of human gastric juice Body Protection Compound (GEPPPGKPADDAGLV). Lyophilized from acetate buffer; reconstitute with bacteriostatic water for in-vitro tissue-repair, angiogenesis, and tendon-fibroblast research.

Purity (HPLC): ≥ 99.18%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$60CAD / 5 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

BPC-157 (Body Protection Compound 157) is a stable 15-residue partial sequence derived from a protein found in human gastric juice. As a research reference standard it is used to investigate angiogenesis, fibroblast migration, and tendon-to-bone healing kinetics in cell-culture and rodent models. The pentadecapeptide retains activity in the gastric environment and shows characteristic stability under acid conditions that distinguishes it from many other peptide standards.

Each vial is lyophilized from acetate-buffered solution, sealed under nitrogen, and held at −20 °C through ship. Cold-chain insulation is maintained from our Kelowna facility to your bench.

Research applications

Tendon-fibroblast outgrowth and migration assays, in-vitro angiogenesis (HUVEC tube-formation), gastrointestinal mucosal-repair models, NO-pathway interaction studies, and growth-factor expression screens. Frequently paired with TB-500 in comparative musculoskeletal-repair protocols.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	GEPPPGKPADDAGLV
Molecular formula	C₆₂H₉₈N₁₆O₂₂
Molecular weight	1419.55 g/mol
CAS number	137525-51-0
Sequence length	15 residues

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot 26-A031: 99.18%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot 26-A031

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Janoshik-tested with independent third-party HPLC verification. Retain samples held under storage spec for five years from release date.

Download COA (PDF · 412 kB)

Verification

Method	Result
RP-HPLC at 220 nm	99.18% main peak
ESI-MS (positive)	1419.6 Da (theor. 1419.55)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–32.

Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–80.

Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333.

Citing this material

BPC-157 reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-BPC157-5, Lot 26-A031.

Related · Healing axis

Often paired in studies.

View catalog →

Healing

TB-500

5 mg · ≥ 99.0%

$70 CADView →

Healing

BPC / TB Blend

10 mg · ≥ 99.0%

$120 CADView →

Cosmetic · Repair

GHK-Cu

50 mg · ≥ 99.2%

$50 CADView →

Immune · Repair

Thymosin Alpha-1

5 mg · ≥ 99.2%

$130 CADView →

Why Lumera

Janoshik Analytical HPLC ≥ 99.18% on this lot
LC-MS identity confirmed before release
LAL endotoxin below detection limit
Cold-chain shipped −20°C from Kelowna, BC

Background research

What the literature says about Bpc 157.

Mechanism

Bpc 157 is Body Protection Compound 157, classified within the tissue-repair pathway. Structurally it is a stable gastric pentadecapeptide BPC 157. Sikiric et al. (2011) characterized BPC-157 as a stable gastric pentadecapeptide derived from human gastric juice. Subsequent in-vitro work has examined its action on tendon-fibroblast outgrowth, gastrointestinal-tract protection, and angiogenesis pathways via VEGFR2/eNOS signaling.

In an in-vitro setting, Bpc 157 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

In-vitro receptor-binding and dose-response screens against the tissue-repair target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Bpc 157's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Bpc 157 arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

Sikiric P et al. Curr Pharm Des. 2011;17(16):1612-32.
Chang CH et al. J Appl Physiol. 2011;110(3):774-80.
Hsieh M-J et al. Mol Med Rep. 2017;15(4):1631-7.

For laboratory research only. Bpc 157 is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.

$60 CAD